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ABSTRACT
Introduction: The Respimat Soft MistTM
Inhaler (SMI) is a hand-held device that
generates an aerosol with a high fine-particle
fraction, enabling efficient lung deposition.
Inhalation therapy for children should be safe
and effective. This study aimed to assess the
success and the quality of inhalation maneuvers
among children using the Respimat SMI.
Methods: This single-center study was
conducted at Mainz University Hospital,
Germany, between March 2006 and August
2006. Ninety-nine children, aged 4–12 years,
with asthma bronchiale or other atopic diseases,
and their healthy siblings were included.
Children with serious respiratory conditions
such as cystic fibrosis or any chronic
destructive or severe lung disease were
excluded. Each child performed three
inhalation maneuvers using the Respimat SMI.
Inspiratory flow rate, inhaled volume, and
timing of actuation for each inhalation
maneuver were recorded using a
pneumotachograph. Successful use and quality
of inhalation maneuvers (inspiratory flow rate,
theoretical inhaled dose fraction, and estimated
lung deposition of the aerosol cloud) were
assessed. Results were compared with respect
to prior experience of inhaler use and between
two age groups (4–8 years and 9–12 years).
Results: Ninety of 99 children achieved one or
more successful maneuver. Overall, 75.1 % of
inhalation maneuvers performed with the
Respimat SMI were successful; the greatest
success was seen in older versus younger
children. Overall median estimated lung
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deposition was 67 %. Median inspiratory flow
was 41.5 L/min, with slower rates noted in the
younger children. Fifty-two percent of children
inhaled faster than 40.0 L/min. Prior inhaler
experience imparted no benefit in terms of
success of inhalation maneuvers, overall, but
was associated with some group differences in
inhalation flow rate.
Conclusion: Children can perform a successful
inhalation maneuver with the Respimat SMI,
with the greatest success rate in children aged
[5 years.
Keywords: Asthma; Device handling;
Inhalation therapy; Pediatric population
INTRODUCTION
Inhalation therapy is a cornerstone in the
management of chronic respiratory diseases.
Direct drug delivery to the lung maximizes
therapeutic outcome at the lowest possible dose
while minimizing unwanted systemic side
effects [1–3]. Treatment success relies on
efficient operation of inhalation devices [4].
For children, achieving effective inhaler use can
be challenging because of their different
physiological characteristics and comparatively
limited coordination [4].
The Respimat Soft MistTM inhaler (SMI) is a
novel, hand-held, propellant-free, multidose
inhalation device that generates a
slow-moving, long-lasting aerosol cloud
containing a high fine-particle fraction that
enables efficient drug delivery to the lungs
[5–10]. For optimal use of the Respimat SMI,
the patient is directed to breathe out slowly and
deeply. After exhalation the patient is asked to
close his or her lips around the end of the
mouthpiece [5]. The dose-release button is then
pressed while the patient takes a slow, deep
inhalation through the mouth; it is
recommended that the patient hold this
breath in for 10 s [5]. Although the Respimat
SMI requires some degree of hand–breath
synchronization, it may offer enhanced drug
delivery in patients who have difficulties in
actuating and coordinating inhalation when
using a pressurized metered dose inhaler (MDI)
[5].
A number of studies have shown that
patients may find it easier to inhale with the
Respimat because of the slow release of the
aerosol—approximately 1.5 s, compared with
approximately 0.2 s for a chlorofluorocarbon
MDI, and 0.3 s for a hydrofluoroalkane MDI—
and low cloud velocity (\0.8 m/s) with the
Respimat [7, 11, 12]. However, it is possible
that longer spray duration could also lead to a
certain ‘‘loss’’ of aerosol, if inspiration stops
before the end of the aerosol release.
A clinical study confirmed that the design
and operative features of the Respimat SMI
allows successful use in the pediatric population
(children aged 6–15 years) and enabled a
twofold reduction in the nominal dose for the
treatment of asthma compared with inhalation
from an MDI with a spacer [9]. The aim of the
current study was to evaluate the use of the
Respimat SMI in children aged 4–12 years.
MATERIALS AND METHODS
Study Design
This single-center study was conducted at
Mainz University Hospital, Germany, between
March 2006 and August 2006. The objective was
to assess the success and quality of inhalation
maneuvers among children using the
Respimat SMI (Boehringer Ingelheim Pharma
GmbH & Co KG, Ingelheim, Germany) in two
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age groups (4–8 years and 9–12 years), and the
influence of prior inhaler experience. The
exclusion of children with serious respiratory
conditions eliminated functional restrictions
and was in line with the study objective to
investigate potential age-related handling issues
with a new SMI. The study was conducted in
accordance with Good Clinical Practice and
applicable regulatory requirements. This was
not a ‘‘clinical trial’’ according to the German
Drug or Medical Devices Act as no medication
was administered. Institutional review board
approval was obtained. All procedures followed
were in accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study.
Study Participants
Children aged 4–12 years, of either sex, with
asthma bronchiale or atopic diseases, and their
healthy siblings were enrolled into the study at
the Pediatric Pulmonology and Allergology
Outpatient Clinic, Mainz University Hospital.
Children with or without previous inhaler
experience were included, and any devices
used in the past 12 months were documented.
Children with serious respiratory conditions
such as cystic fibrosis or any chronic
destructive or severe lung disease were
excluded.
Device and Training
A Respimat SMI training kit that delivered an
aerosol cloud containing no active medication
was used. All children received standardized
training on how to achieve a slow and deep
inhalation maneuver using the training kit.
During the training, the investigator gave
three demonstrations of optimal inhaler
technique (or two demonstrations for children
aged 9–12 years). Next, the child was allowed
three trial inhalations (or two trial inhalations
for children aged 9–12 years) during which the
investigator gave instructions on how to
improve his or her technique, if required.
Training was concluded by a demonstration of
the measurement equipment plus one further
test inhalation. The children were not given any
help using the inhaler from parents or
caregivers, and no accessory devices such as
spacers were used.
Assessments
Maneuver assessment was based on inhalation
flow profiles, recorded using a
pneumotachograph (JAEGER MasterScope,
CareFusion Corporation, Germany) which was
connected to the Respimat SMI. The profiles
included inspiratory flow rate, inhaled volume,
and timing of actuation for each inhalation
maneuver. Three consecutive inhalation
maneuvers, after the training maneuvers, were
recorded and analyzed for each patient during a
single visit.
Maneuver failure was defined as Respimat
SMI actuation errors (i.e., no actuation,
actuation C3 s before inhalation, actuation
after inhalation), exhalation during the
inhalation maneuver (including possible
coughing triggered by inhalation), or
inhalation volume \0.5 L (Fig. 1). If none of
these errors occurred, the inhalation maneuver
was defined as successful.
For each successful maneuver, three
inhalation quality parameters were
determined: the inspiratory flow rate (L/min),
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the theoretical inhaled fraction (%), and the
estimated lung deposition (%) that would have
been achieved. The theoretical inhaled fraction
(i.e., the percentage of the placebo fine aerosol
cloud inhaled by the patient) was calculated
according to spray duration, actuation time
point, and inhalation duration (See Appendix
Fig. A1).
Estimated lung deposition of the placebo
aerosol cloud was calculated by subtracting
the extrathoracic deposition (approximately
proportional to inspiratory flow rate [13]) from
the theoretical inhaled fraction (See Appendix
Fig. A2).
Statistical Analyses
Median values for the three inhalation quality
parameters were recorded for each child who
managed one or more successful inhalation
maneuver. Statistical analyses were carried out
using SPSS (IBM, Armonk, NY, USA [used at
University of Mainz]) and SAS (SAS Institute,
Inc., Cary, NC, USA [used at Boehringer
Ingelheim]). Error rates were calculated for all
inhalation maneuvers combined. Differences in
the frequency of error rates between groups
were analyzed using the Mann–Whitney U test
and logistic regression. Differences in quality
parameters between groups were analyzed using
the Mann–Whitney U test. Linear regression
was used for the analyses of dependency of the
quality parameters and age.
RESULTS
Study Participants
A total of 99 children were enrolled into the
study (n = 59 aged 4–8 years; n = 40 aged
9–12 years). Of these 99 children, 15 had no
previous experience with inhalation devices
because they had not been diagnosed as
having any lung disease, and were hence
described as ‘‘healthy.’’ Demographics and
prior inhaler experience are shown in Table 1.
Inhalation Success
Overall, 223/297 (75.1 %) of the inhalation
maneuvers in 99 children were successful. Of
the 74 unsuccessful maneuvers, 14 (18.9 %)
were due to more than one type of user error.
Actuation error occurred in 33/297 (11.1 %)
maneuvers (3/297 [1.0 %] maneuvers with
actuation after inhalation and 30/297 [10.1 %]
maneuvers with missing actuation), exhalation
occurred in 25/297 (8.4 %) maneuvers, and
inhalation \0.5 L occurred in 33/297 (11.1 %)
maneuvers. The rates of maneuvers with only
one error were actuation error only 27/297
(9.1 %), inhalation volume\0.5 L only 19/297
(6.4 %), and exhalation error only 14/297
(4.7 %).
Fig. 1 Scheme for assessing inhalation maneuvers
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The frequency of successful maneuvers was
numerically higher in the older group of
children than in the younger group (99/120
[82.5 %] vs. 124/177 [70.1 %]); however, there
was no significant difference in error type
between groups (p[0.05). The most frequent
error in children aged 4–8 years was an
inhalation volume \0.5 L, whereas poor
coordination of the dose release with
inhalation was most common in children aged
9–12 years (Fig. 2). None of the children aged
4 years (n = 3 children, nine maneuvers) were
able to perform a successful inhalation, mainly
because of coordination problems. In contrast,
5/12 (41.7 %) maneuvers of children aged
5 years (n = 4) and 24/27 (88.9 %) maneuvers
of those aged 6 years (n = 9) had successful
maneuvers (Appendix Table A1).
Inhalation Quality
Overall, 90 of 99 children managed one or more
successful inhalation maneuvers and only those
children with successful maneuvers were
included in the calculation of inhalation
quality parameters (inspiratory flow rate, the
theoretical inhaled fraction, and the estimated
lung deposition). The median estimated lung
deposition in this group was 66.9 % (Appendix
Fig. A3). A difference in lung deposition was seen
between age groups: children aged 4–8 years
(n = 51) achieved a higher median estimated
lung deposition (74.2 %) than children aged
9–12 years (n = 39) (61.7 %) (Fig. 3a). The linear
regression shows a linear dependency between
age and estimated lung deposition: the older the
child, the lower the estimated lung deposition
(p\0.01) (Fig. 3b). Median inspiratory flow rate
in all 90 children was 41.5 L/min (range,
7.9–113.5 L/min). Flow rate was[40.0 L/min in
52.2 % of children (Appendix Fig. A4).
Inspiratory flow rate was slower in children
aged 4–8 years than in the older group (median
30.6 L/min versus 49.9 L/min) (Fig. 4a). There is a
linear trend between age and inspiratory flow:
the older the child, the higher the flow (p\0.01)
(Fig. 4b). Total inhaled volumes increased with
the age of the children (Appendix Fig. A5).
Table 1 Demographic data and previous experience of using inhalation devices (N = 99)
Total Aged 4–8 years Aged 9–12 years
Patients, n (%) 99 (100) 59 (100) 40 (100)
Male (%) 61 (61.6) 36 (61.0) 25 (62.5)
Mean age (range) 8.7 (4.2–12.8) 7.3 (4.2–8.8) 10.7 (9.0–12.8)
Healthy children,* n (%) 15 (15.2) 10 (17.0) 5 (12.5)
Prior experience with inhalation device, n (%) 84 (85.0) 49 (83.1) 35 (87.5)
DPI 54 (55.0) 26 (44.1) 28 (70.0)
Autohaler 30 (30.0) 13 (22.0) 17 (42.5)
Conventional MDI 12 (12.1) 6 (10.2) 6 (15.0)
Nebulizer/MDI with spacer 36 (36.4) 28 (47.1) 8 (20.1)
The percentages are given for each column separately. Multiple nominations possible
DPI dry powder inhaler, MDI metered dose inhaler
* Had no previous experience with inhalation devices, as they had not been diagnosed as having any lung disease
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Effect of Prior Inhaler Experience
The percentage of successful maneuvers in
children with no previous experience using
inhalation devices was similar to that in
experienced children (73.3 % [33/45] vs.
75.0 % [189/252], p[0.5). Examination of
data according to the type of inhaler
previously used revealed some group
differences: children who had previously used
dry powder inhalers (DPIs), Autohaler (Teva
Deutschland, Ulm, Germany), or MDIs had the
highest success rates (Appendix Fig. A6;
Table 2); the lowest success rate was seen in
children with prior experience using inhalers
with spacer devices (65.7 % [71/108]).
Concerning the inhalation quality
(determined from the 90 children with at least
one successful maneuver), median estimated
lung deposition was comparable in the
nonexperienced and experienced subgroups
(69 vs. 67 %, p[0.1), but was lower in the
group of children experienced with DPIs
relative to those not experienced with DPIs (61
vs. 72 %, p\0.01). Estimated lung deposition
was also lower in children experienced with the
Autohaler versus those with no prior use (60 vs.
71 %, p\0.01). For those who have used an
MDI versus those with no prior use of any MDI
(60 vs. 69 %, p[0.1) there was no influence on
the estimated lung deposition. The highest level
of lung deposition was seen in children with
experience using nebulizers with spacers (72 %).
The median inspiratory flow rate in
nonexperienced children was lower than in
experienced children (29.7 vs. 44.0 L/min).
High median flow rates of 49.9 L/min were
recorded in children who had used a DPI or
Autohaler previously, and of 50.0 L/min in
those experienced with the MDI. A relatively
Fig. 2 Inhalation maneuver success and error types (%) by age group (N = 99)
58 Pulm Ther (2015) 1:53–63
low mean inspiratory flow rate (39 L/min) was
seen among children with experience using
nebulizers or MDIs with spacers.
Of interest, in 42 of 297 (14.1 %) inhalations,
the children momentarily caught their breath
during the test inhalations, causing a sudden
drop in airflow during the inhalation maneuver.
This phenomenon was more common in the
4–8-year-olds (affecting 36/177 [20.3 %]
inhalations) than in the older group (6/120
[5.0 %] inhalations, p\0.05). Since there was
no associated exhalation during these instances,
the maneuvers were classified as successful
unless any of the other two failure criteria
occurred.
DISCUSSION
Efficient respiratory drug delivery to the lungs
relies on the quality of the inhalation
maneuver, which is in turn influenced by
device design characteristics. The Respimat
SMI generates a slow-moving aerosol cloud
that is independent of inspiratory flow rate [7,
13, 14].
The objective of the current study was to assess
the success of inhalation maneuvers and the
quality of inhalation breathing patterns among
children aged 4–12 years using Respimat SMI;
other aspects of device handling were not
evaluated. The high percentage of successful
Fig. 3 a Median estimated lung deposition in each age
group, and b estimated lung deposition (best of three
attempts) versus age (N = 90 children with successful
maneuvers)
Fig. 4 a Median inspiratory ﬂow rate in each age group,
and b mean inspiratory ﬂow rate versus age (N = 90
children with successful maneuvers)
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inhalation maneuvers (&75 %) in children aged
C5 years suggests that these children are able to
use the Respimat SMI correctly without adult
assistance or breathing aids (e.g., spacer).
Conversely, children aged below 5 years are less
able to perform a successful inhalation maneuver
with the Respimat SMI; however, information is
limited, as only three children aged 4 years were
included. These younger children had problems
coordinating actuation and inspiration, inhaling
slowly and continuously, and holding their
breath after inhaling. However, in these
children, successful inhalation can be achieved
using a spacer and with parental/caregiver help,
as appropriate to their age [15].
In a previous study of children aged 4–14 years
using other devices, the rate of correct inhalation
maneuvers achieved after training was 88.5 %
with the Diskus (GlaxoSmithKline GmbH & Co.
KG, Munich, Germany), 65.4 % with the
Turbohaler (AstraZeneca GmbH, Wedel,
Germany), and 42.3 % with the Autohaler [16].
The rate of successful inhalation maneuvers in
this study was 75.1 % overall, and 82.5 % in
children aged 9–12 years. Although it is necessary
to be cautious when comparing across studies,
these results suggest that the ease of operating the
Respimat SMI compares favorably with the
Turbohaler and the Diskus DPI, both of which,
unlike the Respimat SMI, require active
inspiratory effort to overcome device resistance
and achieve adequate drug delivery to the
airways. The delivery of drug by the Respimat
SMI is independent of inspiratory flow rate and
efforts, in contrast to other devices, including
DPIs such as the Turbohaler and the Diskus DPI,
which require breath actuation, involving
inspiratory effort and a need for a certain flow
rate [2, 4, 17, 18].
In this study, only a small proportion of the
errors recorded were device related (i.e., errors
in coordinating dose release with inhalation,
which occur with all manually operated
devices, or exhalation errors caused by
coughing in response to inhalation). The rate
of device-related errors (11 %) is comparable to
that associated with other devices [19]. The rate
of inhalation maneuver success with the
Respimat SMI was 73 % in children with no
prior experience using inhalers, suggesting that
those naı¨ve to such devices can operate the
Respimat SMI without difficulty. Children naı¨ve
Table 2 Breathing maneuver quality according to prior experience with inhalers (N = 99 for inhaler experiencea; N = 90









N (children) 15 84 54 30 12 36
Children with successful
maneuvers, n (%)
11 (73.3) 63 (75.0) 46 (85.2) 25 (83.3) 10 (83.3) 24 (66.7)
Median estimated
lung deposition (%)
69 67 61 60 60 72
Median inspiratory
ﬂow rate (L/min)
30 44 50 50 50 39
The percentages are given for each column separately
DPI dry powder inhaler, MDI metered dose inhaler
a Multiple nominations possible
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to inhalers and those in the younger age group
did appear to be more susceptible to the
‘‘breath-catching phenomenon’’ in response to
inhalation; however, this response alone did
not determine inhalation maneuver failure.
Children who had previously used DPIs,
Autohaler, or pressurized MDIs achieved the
highest percentages of successful maneuvers
with the Respimat SMI, indicating that some
device experience of this kind supports
Respimat SMI operation. In contrast, prior
experience using nebulizers or a pressurized
MDI with a spacer provided no benefit in terms
of ensuring correct inhalation via Respimat
SMI. This may be because subjects are taking
multiple breaths (tidal breathing) rather than a
single deep breath or it may be influenced by
the likely prior use of nebulizers and spacers in
children with low levels of coordination (e.g.,
because of their young age).
The median estimated lung deposition
recorded in the group of children aged
9–12 years was lower than in those aged
4–8 years. This is explained by higher inspiratory
flow rates during inhalation maneuvers in older
children, since the higher the inspiratory flow
rate, the greater the deposition of drug in the
oropharyngeal regionrather than in the lungs [13,
20]. Only 48 % of children in the total group
inhaled within the optimal flow range of\40 L/
min, and in some children the inhalation flow
rate reached beyond 100 L/min. In contrast to the
Respimat SMI, DPIs in particular require a high
inspiratory flow rate for effective drug delivery
and users need to overcome a trigger threshold;
children with experience using DPI were,
therefore, trained to inhale as quickly and
deeply as possible. In the current study, children
with experience using DPIs inhaled faster than
those without such background.
Although overall maneuver success rates were
lowest in the subgroup of children who had
previously used spacers, the median inspiratory
flow rate from successful inhalations was\40 L/
min, which led to a higher median estimated
lung deposition than in children who had used
other inhaler devices, and was similar to those
without prior inhaler experience.
The interpretation of the results from this
study is limited by a number of factors, among
which are the number of participants and the
pneumotachograph, which was added to the
inhaler and made handling more difficult.
Furthermore, estimated lung deposition was a
calculated value and, therefore, only partially
comparable with scintigraphic data, and did not
take into account device deposition or losses
due to re-exhaled aerosol. Pitcairn et al. [8]
showed in a scintigraphic study a lung
deposition of 51.6 % after an ideal inhalation
maneuver. However, the loss due to device
deposition and re-exhaled aerosol accounts for
the loss of &27 % of the dose, predicting a
median estimated lung deposition of 73 % [8]
and supporting the plausibility of the results. In
this study, a corresponding maneuver (i.e., ideal
coordination and inspiratory flow 26 L/min)
shows an estimated lung deposition of 83 %,
thus somewhat overestimating the results from
scintigraphic studies. A strength of this study is
that estimated data in children were obtained,
which circumvented the need for actual drug
deposition scintigraphic studies.
CONCLUSION
These findings demonstrate that children aged
5 years and older can use the Respimat SMI and
perform a successful inhalation maneuver;
while children aged 4 years did not meet the
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success criteria. Children aged 5–8 years
achieved higher estimated lung deposition
values than children aged 9–12 years, possibly
owing to a higher inspiratory flow rate (and,
therefore, greater extrathoracic deposition) in
the older group.
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